Literature DB >> 16695935

Usefulness of chromic oxide as an internal standard for balance studies in formula-fed patients and for assessment of colonic function.

J Davignon1, W J Simmonds, E H Ahrens.   

Abstract

In 35 patients maintained solely on liquid formula diets, chromic oxide has been evaluated as an internal standard for balance studies that require stool collections. In 28 patients the excretion of chromic oxide was ideal: steady states were attained in which mean daily output was 90% (or more) of mean daily intake. In these patients corrections for fecal flow could validly be applied.In patients who excreted the marker ideally, the availability of chromic oxide balance data made possible the calculation of pool sizes and turnover rates of unexcreted intestinal content. These indexes bore little relationship to the usual clinical descriptions of bowel habits. In some patient who had daily bowel movements, pool sizes were very large and daily turnover was small, i.e., a large proportion of the colonic contents was not excreted for surprisingly long periods. It is critically important for investigators to recognize this possibility when carrying out balance studies for fecal constituents that may be altered by bacterial action within the gut lumen: for instance, in 6 patients a significant inverse correlation was found between daily fecal turnover and degradative losses of large amounts of dietary beta-sitosterol.7 of 35 patients failed to attain the ideal steady state of chromic oxide excretion. These patients would not have been singled out if an internal standard had not been used. In such patients balance studies that require analysis of fecal constituents must be interpreted with great caution, since the constituents in question may be handled in the same nonideal fashion as the internal standard.

Entities:  

Year:  1968        PMID: 16695935      PMCID: PMC297154          DOI: 10.1172/JCI105703

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  12 in total

1.  LOWERING OF CHOLESTEROL ABSORPTION AND BLOOD LEVELS BY ILEAL EXCLUSION. EXPERIMENTAL BASIS AND PRELIMINARY CLINICAL REPORT.

Authors:  H BUCHWALD
Journal:  Circulation       Date:  1964-05       Impact factor: 29.690

2.  QUANTITATIVE ISOLATION AND GAS--LIQUID CHROMATOGRAPHIC ANALYSIS OF TOTAL DIETARY AND FECAL NEUTRAL STEROIDS.

Authors:  T A MIETTINEN; E H AHRENS; S M GRUNDY
Journal:  J Lipid Res       Date:  1965-07       Impact factor: 5.922

3.  Experience with the chromic oxide method of fecal marking in metabolic balance investigations on humans.

Authors:  L G WHITBY; D LANG
Journal:  J Clin Invest       Date:  1960-06       Impact factor: 14.808

4.  Study of urinary and fecal excretion of radioactive chromium Cr51 in man; its use in the measurement of intestinal blood loss associated with hookworm infection.

Authors:  M ROCHE; M E PEREZ-GIMENEZ; M LAYRISSE; M E DI PRISCO
Journal:  J Clin Invest       Date:  1957-07       Impact factor: 14.808

5.  Excretion from the gut and gastrointestinal exchange; studied by means of the inert indicator method.

Authors:  M M STANLEY; S H CHENG
Journal:  Am J Dig Dis       Date:  1957-11

6.  The turnover of bile acids in the rat; bile acids and steroids 39.

Authors:  S LINDSTEDT; A NORMAN
Journal:  Acta Physiol Scand       Date:  1956-12-31

7.  A simplified method for the determination of chromic oxide (Cr2 O3) when used as an index substance.

Authors:  D W BOLIN; R P KING; E W KLOSTERMAN
Journal:  Science       Date:  1952-12-05       Impact factor: 47.728

8.  Absorption of carotene from carrots in man and the use of the quantitative chromic oxide indicator method in the absorption experiments.

Authors:  M S Kreula
Journal:  Biochem J       Date:  1947       Impact factor: 3.857

9.  The use of orally-fed liquid formulas in metabolic studies.

Authors:  E H AHRENS; V P DOLE; D H BLANKENHORN
Journal:  Am J Clin Nutr       Date:  1954 Sep-Oct       Impact factor: 7.045

10.  The use of chromic oxide as an index material in digestion trials with human subjects.

Authors:  M I IRWIN; E W CRAMPTON
Journal:  J Nutr       Date:  1951-01       Impact factor: 4.798

View more
  37 in total

1.  Transit through the gut measured by analysis of a single stool.

Authors:  J H Cummings; H S Wiggins
Journal:  Gut       Date:  1976-03       Impact factor: 23.059

2.  Faecal bile acid loss and bile acid pool size during short-term treatment with ursodeoxycholic and chenodeoxycholic acid in patients with radiolucent gallstones.

Authors:  G Salvioli; R Salati
Journal:  Gut       Date:  1979-08       Impact factor: 23.059

3.  Polyethylene glycol 4000 as a continuously administered non-absorbable faecal marker for metabolic balance studies in human subjects.

Authors:  R Wilkinson
Journal:  Gut       Date:  1971-08       Impact factor: 23.059

4.  Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.

Authors:  S M Grundy; D W Bilheimer
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

5.  Treatment of familial hypercholesterolemia by portacaval anastomosis: effect on cholesterol metabolism and pool sizes.

Authors:  D J McNamara; E H Ahrens; R Kolb; C D Brown; T S Parker; N O Davidson; P Samuel; R M McVie
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

6.  Serum cholesterol precursor sterols in coeliac disease: effects of gluten free diet and cholestyramine.

Authors:  M Vuoristo; T A Miettinen
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

7.  Influence of age, intestinal transit time, and dietary composition on fecal bile acid profiles in healthy subjects.

Authors:  F M Nagengast; S D van der Werf; H L Lamers; M P Hectors; W C Buys; J M van Tongeren
Journal:  Dig Dis Sci       Date:  1988-06       Impact factor: 3.199

8.  The effects of unsaturated dietary fats on absorption, excretion, synthesis, and distribution of cholesterol in man.

Authors:  S M Grundy; E H Ahrens
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

9.  Absorption and metabolic fate of dietary 3H-squalene in the rat.

Authors:  R S Tilvis; T A Miettinen
Journal:  Lipids       Date:  1983-03       Impact factor: 1.880

10.  Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes.

Authors:  Y A Kesäniemi; T A Miettinen; M P Salaspuro
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.